Literature DB >> 10196302

Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains.

A L Edinger1, C Blanpain, K J Kunstman, S M Wolinsky, M Parmentier, R W Doms.   

Abstract

With rare exceptions, all simian immunodeficiency virus (SIV) strains can use CCR5 as a coreceptor along with CD4 for viral infection. In addition, many SIV strains are capable of using CCR5 as a primary receptor to infect CD4-negative cells such as rhesus brain capillary endothelial cells. By using coupled fluorescence-activated cell sorter (FACS) and infection assays, we found that even very low levels of CCR5 expression could support CD4-independent virus infection. CD4-independent viruses represent valuable tools for finely dissecting interactions between Env and CCR5 which may otherwise be masked due to the stabilization of these contacts by Env-CD4 binding. Based on the ability of SIV Env to bind to and mediate infection of cells expressing CCR5 chimeras and mutants, we identified the N terminus of CCR5 as a critical domain for direct Env binding and for supporting CD4-independent virus infection. However, the activity of N-terminal domain CCR5 mutants could be rescued by the presence of CD4, indicating that other regions of CCR5 are important for post-binding events that lead to viral entry. Rhesus CCR5 supported CD4-independent infection and direct Env binding more efficiently than did human CCR5 due to a single amino acid difference in the N terminus. Interestingly, uncleaved, oligomeric SIV Env protein bound to both CD4 and CCR5 less efficiently than did monomeric gp120. Finally, several mutations present in chronically infected monkey populations are shown to decrease the ability of CCR5 to serve as a primary viral receptor for the SIV isolates examined.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196302      PMCID: PMC104185     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  64 in total

1.  CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5.

Authors:  A Trkola; T Dragic; J Arthos; J M Binley; W C Olson; G P Allaway; C Cheng-Mayer; J Robinson; P J Maddon; J P Moore
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

2.  CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5.

Authors:  L Wu; N P Gerard; R Wyatt; H Choe; C Parolin; N Ruffing; A Borsetti; A A Cardoso; E Desjardin; W Newman; C Gerard; J Sodroski
Journal:  Nature       Date:  1996-11-14       Impact factor: 49.962

3.  Utilization of C-C chemokine receptor 5 by the envelope glycoproteins of a pathogenic simian immunodeficiency virus, SIVmac239.

Authors:  L Marcon; H Choe; K A Martin; M Farzan; P D Ponath; L Wu; W Newman; N Gerard; C Gerard; J Sodroski
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

4.  Genetically divergent strains of simian immunodeficiency virus use CCR5 as a coreceptor for entry.

Authors:  Z Chen; P Zhou; D D Ho; N R Landau; P A Marx
Journal:  J Virol       Date:  1997-04       Impact factor: 5.103

5.  Isolation of a T-lymphotropic retrovirus from naturally infected sooty mangabey monkeys (Cercocebus atys).

Authors:  P N Fultz; H M McClure; D C Anderson; R B Swenson; R Anand; A Srinivasan
Journal:  Proc Natl Acad Sci U S A       Date:  1986-07       Impact factor: 11.205

6.  Genetic diversity of simian immunodeficiency viruses from West African green monkeys: evidence of multiple genotypes within populations from the same geographical locale.

Authors:  F Bibollet-Ruche; C Brengues; A Galat-Luong; G Galat; X Pourrut; N Vidal; F Veas; J P Durand; G Cuny
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

7.  Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist.

Authors:  G Simmons; P R Clapham; L Picard; R E Offord; M M Rosenkilde; T W Schwartz; R Buser; T N Wells; A E Proudfoot
Journal:  Science       Date:  1997-04-11       Impact factor: 47.728

8.  A seven-transmembrane domain receptor involved in fusion and entry of T-cell-tropic human immunodeficiency virus type 1 strains.

Authors:  J F Berson; D Long; B J Doranz; J Rucker; F R Jirik; R W Doms
Journal:  J Virol       Date:  1996-09       Impact factor: 5.103

9.  CD4, CXCR-4, and CCR-5 dependencies for infections by primary patient and laboratory-adapted isolates of human immunodeficiency virus type 1.

Authors:  S L Kozak; E J Platt; N Madani; F E Ferro; K Peden; D Kabat
Journal:  J Virol       Date:  1997-02       Impact factor: 5.103

10.  CD4-independent infection by HIV-2 is mediated by fusin/CXCR4.

Authors:  M J Endres; P R Clapham; M Marsh; M Ahuja; J D Turner; A McKnight; J F Thomas; B Stoebenau-Haggarty; S Choe; P J Vance; T N Wells; C A Power; S S Sutterwala; R W Doms; N R Landau; J A Hoxie
Journal:  Cell       Date:  1996-11-15       Impact factor: 41.582

View more
  46 in total

1.  Characterization and epitope mapping of neutralizing monoclonal antibodies produced by immunization with oligomeric simian immunodeficiency virus envelope protein.

Authors:  A L Edinger; M Ahuja; T Sung; K C Baxter; B Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2000-09       Impact factor: 5.103

Review 2.  Lentiviral neuropathogenesis: comparative neuroinvasion, neurotropism, neurovirulence, and host neurosusceptibility.

Authors:  Megan K Patrick; James B Johnston; Christopher Power
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

3.  Sensitivity of HIV-1 to entry inhibitors correlates with envelope/coreceptor affinity, receptor density, and fusion kinetics.

Authors:  Jacqueline D Reeves; Stephen A Gallo; Navid Ahmad; John L Miamidian; Phoebe E Harvey; Matthew Sharron; Stefan Pohlmann; Jeffrey N Sfakianos; Cynthia A Derdeyn; Robert Blumenthal; Eric Hunter; Robert W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-20       Impact factor: 11.205

4.  Use of a gp120 binding assay to dissect the requirements and kinetics of human immunodeficiency virus fusion events.

Authors:  B J Doranz; S S Baik; R W Doms
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

5.  Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120.

Authors:  K Salzwedel; E D Smith; B Dey; E A Berger
Journal:  J Virol       Date:  2000-01       Impact factor: 5.103

6.  The Src kinase Lyn is required for CCR5 signaling in response to MIP-1beta and R5 HIV-1 gp120 in human macrophages.

Authors:  Brian Tomkowicz; Chuhee Lee; Vipa Ravyn; Ricky Cheung; Andrzej Ptasznik; Ronald G Collman
Journal:  Blood       Date:  2006-04-18       Impact factor: 22.113

7.  A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response.

Authors:  Peng Fei Zhang; Peter Bouma; Eun Ju Park; Joseph B Margolick; James E Robinson; Susan Zolla-Pazner; Michael N Flora; Gerald V Quinnan
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

8.  Simian immunodeficiency viruses of diverse origin can use CXCR4 as a coreceptor for entry into human cells.

Authors:  S M Owen; S Masciotra; F Novembre; J Yee; W M Switzer; M Ostyula; R B Lal
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

9.  Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis.

Authors:  Juan T Borda; Xavier Alvarez; Ivanela Kondova; Pyone Aye; Meredith A Simon; Ronald C Desrosiers; Andrew A Lackner
Journal:  Am J Pathol       Date:  2004-12       Impact factor: 4.307

10.  CD4-independent use of Rhesus CCR5 by human immunodeficiency virus Type 2 implicates an electrostatic interaction between the CCR5 N terminus and the gp120 C4 domain.

Authors:  G Lin; B Lee; B S Haggarty; R W Doms; J A Hoxie
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.